Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas
Transcription factor NRF2 orchestrates a cellular defense against oxidative stress and, so far, has been involved in tumor progression by providing a metabolic adaptation to tumorigenic demands and resistance to chemotherapeutics. In this study, we discover that NRF2 also propels tumorigenesis in gl...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-02-01
|
| Series: | Redox Biology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231719312807 |
| _version_ | 1819087528833056768 |
|---|---|
| author | Maribel Escoll Diego Lastra Marta Pajares Natalia Robledinos-Antón Ana I. Rojo Raquel Fernández-Ginés Marta Mendiola Virginia Martínez-Marín Isabel Esteban Pilar López-Larrubia Ricardo Gargini Antonio Cuadrado |
| author_facet | Maribel Escoll Diego Lastra Marta Pajares Natalia Robledinos-Antón Ana I. Rojo Raquel Fernández-Ginés Marta Mendiola Virginia Martínez-Marín Isabel Esteban Pilar López-Larrubia Ricardo Gargini Antonio Cuadrado |
| author_sort | Maribel Escoll |
| collection | DOAJ |
| description | Transcription factor NRF2 orchestrates a cellular defense against oxidative stress and, so far, has been involved in tumor progression by providing a metabolic adaptation to tumorigenic demands and resistance to chemotherapeutics. In this study, we discover that NRF2 also propels tumorigenesis in gliomas and glioblastomas by inducing the expression of the transcriptional co-activator TAZ, a protein of the Hippo signaling pathway that promotes tumor growth. The expression of the genes encoding NRF2 (NFE2L2) and TAZ (WWTR1) showed a positive correlation in 721 gliomas from The Cancer Genome Atlas database. Moreover, NRF2 and TAZ protein levels also correlated in immunohistochemical tissue arrays of glioblastomas. Genetic knock-down of NRF2 decreased, while NRF2 overexpression or chemical activation with sulforaphane, increased TAZ transcript and protein levels. Mechanistically, we identified several NRF2-regulated functional enhancers in the regulatory region of WWTR1. The relevance of the new NRF2/TAZ axis in tumorigenesis was demonstrated in subcutaneous and intracranial grafts. Thus, intracranial inoculation of NRF2-depleted glioma stem cells did not develop tumors as determined by magnetic resonance imaging. Forced TAZ overexpression partly rescued both stem cell growth in neurospheres and tumorigenicity. Hence, NRF2 not only enables tumor cells to be competent to proliferate but it also propels tumorigenesis by activating the TAZ-mediated Hippo transcriptional program. Keywords: Oxidative stress, Cancer stem cells, Chemotherapy, Glioblastoma |
| first_indexed | 2024-12-21T21:37:35Z |
| format | Article |
| id | doaj.art-b8990445efe3436cb0fdd0576778f576 |
| institution | Directory Open Access Journal |
| issn | 2213-2317 |
| language | English |
| last_indexed | 2024-12-21T21:37:35Z |
| publishDate | 2020-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Redox Biology |
| spelling | doaj.art-b8990445efe3436cb0fdd0576778f5762022-12-21T18:49:27ZengElsevierRedox Biology2213-23172020-02-0130Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomasMaribel Escoll0Diego Lastra1Marta Pajares2Natalia Robledinos-Antón3Ana I. Rojo4Raquel Fernández-Ginés5Marta Mendiola6Virginia Martínez-Marín7Isabel Esteban8Pilar López-Larrubia9Ricardo Gargini10Antonio Cuadrado11Instituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Spain; Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Madrid, SpainInstituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Spain; Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Madrid, SpainInstituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Spain; Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Madrid, SpainInstituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Spain; Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Madrid, SpainInstituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Spain; Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Madrid, SpainInstituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Spain; Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Madrid, SpainLaboratory of Pathology and Translational Oncology, Instituto de Investigación Sanitaria La Paz (IdiPaz), Madrid, SpainDepartment of Pathology, Instituto de Investigación Sanitaria La Paz (IdiPaz), Madrid, SpainDepartment of Pathology, Instituto de Investigación Sanitaria La Paz (IdiPaz), Madrid, SpainInstituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), SpainCentro de Biología Molecular “Severo Ochoa” UAM-CSIC, Autonomous University of Madrid, Madrid, SpainInstituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Spain; Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Madrid, Spain; Corresponding author. Instituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, C/ Arturo Duperier, 4, 28029, Madrid, Spain.Transcription factor NRF2 orchestrates a cellular defense against oxidative stress and, so far, has been involved in tumor progression by providing a metabolic adaptation to tumorigenic demands and resistance to chemotherapeutics. In this study, we discover that NRF2 also propels tumorigenesis in gliomas and glioblastomas by inducing the expression of the transcriptional co-activator TAZ, a protein of the Hippo signaling pathway that promotes tumor growth. The expression of the genes encoding NRF2 (NFE2L2) and TAZ (WWTR1) showed a positive correlation in 721 gliomas from The Cancer Genome Atlas database. Moreover, NRF2 and TAZ protein levels also correlated in immunohistochemical tissue arrays of glioblastomas. Genetic knock-down of NRF2 decreased, while NRF2 overexpression or chemical activation with sulforaphane, increased TAZ transcript and protein levels. Mechanistically, we identified several NRF2-regulated functional enhancers in the regulatory region of WWTR1. The relevance of the new NRF2/TAZ axis in tumorigenesis was demonstrated in subcutaneous and intracranial grafts. Thus, intracranial inoculation of NRF2-depleted glioma stem cells did not develop tumors as determined by magnetic resonance imaging. Forced TAZ overexpression partly rescued both stem cell growth in neurospheres and tumorigenicity. Hence, NRF2 not only enables tumor cells to be competent to proliferate but it also propels tumorigenesis by activating the TAZ-mediated Hippo transcriptional program. Keywords: Oxidative stress, Cancer stem cells, Chemotherapy, Glioblastomahttp://www.sciencedirect.com/science/article/pii/S2213231719312807 |
| spellingShingle | Maribel Escoll Diego Lastra Marta Pajares Natalia Robledinos-Antón Ana I. Rojo Raquel Fernández-Ginés Marta Mendiola Virginia Martínez-Marín Isabel Esteban Pilar López-Larrubia Ricardo Gargini Antonio Cuadrado Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas Redox Biology |
| title | Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas |
| title_full | Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas |
| title_fullStr | Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas |
| title_full_unstemmed | Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas |
| title_short | Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas |
| title_sort | transcription factor nrf2 uses the hippo pathway effector taz to induce tumorigenesis in glioblastomas |
| url | http://www.sciencedirect.com/science/article/pii/S2213231719312807 |
| work_keys_str_mv | AT maribelescoll transcriptionfactornrf2usesthehippopathwayeffectortaztoinducetumorigenesisinglioblastomas AT diegolastra transcriptionfactornrf2usesthehippopathwayeffectortaztoinducetumorigenesisinglioblastomas AT martapajares transcriptionfactornrf2usesthehippopathwayeffectortaztoinducetumorigenesisinglioblastomas AT nataliarobledinosanton transcriptionfactornrf2usesthehippopathwayeffectortaztoinducetumorigenesisinglioblastomas AT anairojo transcriptionfactornrf2usesthehippopathwayeffectortaztoinducetumorigenesisinglioblastomas AT raquelfernandezgines transcriptionfactornrf2usesthehippopathwayeffectortaztoinducetumorigenesisinglioblastomas AT martamendiola transcriptionfactornrf2usesthehippopathwayeffectortaztoinducetumorigenesisinglioblastomas AT virginiamartinezmarin transcriptionfactornrf2usesthehippopathwayeffectortaztoinducetumorigenesisinglioblastomas AT isabelesteban transcriptionfactornrf2usesthehippopathwayeffectortaztoinducetumorigenesisinglioblastomas AT pilarlopezlarrubia transcriptionfactornrf2usesthehippopathwayeffectortaztoinducetumorigenesisinglioblastomas AT ricardogargini transcriptionfactornrf2usesthehippopathwayeffectortaztoinducetumorigenesisinglioblastomas AT antoniocuadrado transcriptionfactornrf2usesthehippopathwayeffectortaztoinducetumorigenesisinglioblastomas |